1 describe improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL) who were treated with venetoclax, a drug that targets BCL2 protein. Patients with CLL are known to have skeletal problems. Data for 21,015 patients recently presented at the 57th Annual Meeting of the American Society of Hematology convincingly showed that even untreated patients with CLL have poor bone health and a significantly increased risk of fracture, particularly of the spine and pelvis.
Dr. Roberts and colleagues reply: In response to Zaman and Savendahl: in the venetoclax trial, fractures were reported in 6 of 116 patients (two femoral, two upper limb, one lumbar vertebral, and one facial). The trial design and relatively short-term median follow-up of 17 months preclude any precise estimation of the rate of bone fracture for patients receiving venetoclax therapy. The clinical implications of the genetic data are unclear, given the multiplicity of effects of loss of BCL2 on both osteoblasts and osteoclasts.
1,2 Furthermore, unlike genetic loss, pharmacologic antagonism may not deplete BCL2 function completely. Thus, we agree that it could be informative to include biomarkers of bone turnover in future studies of BCL2-inhibitor therapy, and estimates of fracture incidence could be generated from pooled safety data from current venetoclax trials after longer follow-up. 
